Drug Trial Radar · NCT07849465
Hyperbaric Oxygen Therapy for Veterans With TBI and PCS: A Biomarker Study
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
34
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Oct 1, 2027
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- Summit Hyperbarics and WellnessAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to examine changes in blood biomarkers following hyperbaric oxygen therapy (HBOT) in military veterans with traumatic brain injury and persistent post-concussive symptoms. The main questions it aims to answer are: 1. Does HBOT produce measurable changes in inflammatory, neurotrophic, and neuronal injury biomarkers from baseline to completion of a 40-session treatment protocol in veterans with TBI and PCS? 2. Does the presence of comorbid PTSD influence biomarker responses to HBOT among veterans with TBI and PCS? Participants will: Complete medical and behavioral health evaluations to determine eligibility. Provide blood samples before treatment and after the final session. Receive 40 HBOT sessions at 2.0 ATA, generally two sessions per day with at least four hours between sessions. Approximately 34 veterans will participate. All participants will receive HBOT; there is no comparison group.
Conditions
- Traumatic Brain Injury (TBI) Patients
- Post Concussive Symptoms
- PTSD
Interventions
Hyperbaric Oxygen Therapy (HBOT)Drug
Hyperbaric Oxygen Therapy (HBOT): Participants will complete 40 sessions at 2.0 atmospheres absolute (ATA). Each session includes two 30-minute periods of breathing 100% oxygen, separated by a 5-minute air break. Sessions are generally scheduled twice daily with at least four hours between them.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in blood C-reactive protein (CRP) concentrationTime frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
- Change in blood interleukin-1 (IL-1) concentrationTime frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
- Change in blood interleukin-6 (IL-6) concentrationTime frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
- Change in blood interleukin-10 (IL-10) concentrationTime frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
- Change in blood tumor necrosis factor-alpha (TNF-α) concentrationTime frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
- Change in blood brain-derived neurotrophic factor (BDNF) concentrationTime frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
- Change in blood neurofilament light chain (NfL) concentrationTime frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
- Change in blood glial fibrillary acidic protein (GFAP) concentrationTime frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks)
- Change in blood brain-derived tau (BD-tau) concentrationTime frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
- Change in blood ubiquitin C-terminal hydrolase L1 (UCH-L1) concentrationTime frame: Baseline and after completion of 40 HBOT sessions (approximately 4 weeks).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Summit Hyperbarics and Wellness
Boise, Idaho · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.